Humacyte recently reported research showing its acellular tissue engineered vessel (ATEV) used for dialysis access can self-repair after repeated needle cannulation, maintaining structural integrity ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

Thank you, Tom and good morning, everyone and thank you for joining us for our first quarter 2025 financial results and ...

On May 4, 2026, Humacyte disclosed that it received a notice from Nasdaq staff stating the company’s shares had closed below the $1.00 minimum bid requirement for 30 consecutive business days ended ...

Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - - The ATEV was observed to maintain long-term ...

In the latest trading session, Humacyte, Inc. (HUMA) closed at $5.17, marking a -1.34% move from the previous day. This change lagged the S&P 500's daily loss of 0.16%. Elsewhere, the Dow saw an ...

DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company ...

Humacyte, Inc. (NASDAQ:HUMA) is moving higher on Monday after receiving the Food and Drug Administration’s Regenerative Medicine Advanced Therapy (RMAT) designation for its Acellular Tissue Engineered ...

Humacyte (HUMA) said on Tuesday that it has entered into a credit facility with Avenue Venture Opportunities Fund, providing up to $77.5M in principal amount of new financing.  The credit agreement, ...

Laboratory and preclinical models demonstrate biovascular pancreas platform technology may provide method to transplant islet cells that produce insulin in Type 1 diabetes patients Data presented at ...